Imatinib Therapy for Patients with Chronic Myelogenous Leukemia: Are Patients Living Longer?

Clinical Cancer Research

Volumn 10, Issue 1 I, 2004, Pages 1-3

  DeAngelo, Daniel J ^a,b   Ritz, Jerome ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; BUSULFAN; CYTARABINE; HYDROXYUREA; IMATINIB; INTERFERON; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR;

ALLOGENIC BONE MARROW TRANSPLANTATION; APOPTOSIS; BLAST TRANSFORMATION; CANCER GROWTH; CANCER REGRESSION; CANCER SURVIVAL; CELL DEATH; CELL PROLIFERATION; CHROMOSOME 22; CHROMOSOME 9; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOGENETICS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; EDITORIAL; ENZYME ACTIVITY; ENZYME INHIBITION; FOLLOW UP; FUSION GENE; GENE FUNCTION; HIGH RISK PATIENT; HUMAN; LEUKEMIA CELL; MINIMAL RESIDUAL DISEASE; OUTCOMES RESEARCH; PATIENT SELECTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECIPROCAL CHROMOSOME TRANSLOCATION; SIGNAL TRANSDUCTION; SURVIVAL RATE; TREATMENT FAILURE;

ANTINEOPLASTIC AGENTS; HUMANS; LEUKEMIA, MYELOID, CHRONIC-PHASE; PIPERAZINES; PROGNOSIS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; SURVIVAL RATE;

EID: 1642535528     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-1218-3     Document Type: Editorial

References (11)

1. Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., and Lydon, N. B. Effects of a selective inhibitor of the Ab1 tyrosine kinase on the growth of Bcr-Ab1 positive cells. Nat. Med., 2: 561-566, 1996.
2. Kantarjian, H., Sawyers, C., Hochhaus, A., Guilhot, F., Schiffer, C., Gambacorti-Passerini, C., Niederwieser, D., Resta, D., Capdeville, R., Zoellner, U., Talpaz, M., Druker, B., Goldman, J., O'Brien, S. G., Russell, N., Fischer, T., Ottmann, O., Cony-Makhoul, P., Facon, T., Stone, R., Miller, C., Tallman, M., Brown, R., Schuster, M., Loughran, T., Gratwohl, A., Mandelli, F., Saglio, G., Lazzarino, M., Russo, D., Baccarani, M., and Morra, E. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N. Engl. J. Med., 346: 645-652, 2002.
3. O'Brien, S. G., Guilhot, F., Larson, R. A., Gathmann, I., Baccarani, M., Cervantes, F., Comelissen, J. J., Fischer, T., Hochhaus, A., Hughes, T., Lechner, K., Nielsen, J. L., Rousselot, P., Reiffers, J., Saglio, G., Shepherd, J., Simonsson, B., Gratwohl, A., Goldman, J. M., Kantarjian, H., Taylor, K., Verhoef, G., Bolton, A. E., Capdeville, R., and Druker, B. J. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med., 348: 994-1004, 2003.
4. Hehlmann, R., Heimpel, H., Hasford, J., Kolb, H. J., Pralle, H., Hossfeld, D. K., Queisser, W., Loffler, H., Hochhaus, A., Heinze, B., et al. Randomized comparison of interferon-α with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood, 84: 4064-4077, 1994.
5. Interferon α-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. N. Engl. J. Med., 330: 820-825, 1994.
6. Kantarjian, H., O'Brien, S. G., Cortes, J., Giles, F., Shan, J., Rios, M. B., Faderl, S., Verstovsek, S., Garcia-Manero, G., Wierda, W., Komblau, S., Ferrajoli, A., Keating, M., and Talpaz, M. Survival advantage with imatinib mesylate therapy in chronic phase chronic myelogenous leukemia (CML-CP) post interferon α failure and in late CML-CP: comparison to historical controls. Clin. Cancer Res., 10: 68-75, 2004.
7. Marin, D., Marktel, S., Szydlo, R., Klein, J. P., Bua, M., Foot, N., Olavarria, E., Shepherd, P., Kanfer, E., Goldman, J. M., and Apperley, J. F. Survival of patients with chronic-phase chronic myeloid leukaemia on imatinib after failure on interferon α. Lancet, 362: 617-619, 2003.
8. Wu, C. J., Neuberg, D., Chillemi, A., McLaughlin, S., Hochberg, E. P., Galinsky, I., DeAngelo, D., Soiffer, R. J., Alyea, E. P., Capdeville, R., Stone, R. M., and Ritz, J. Quantitative monitoring of BCR/ABL transcript during STI-571 therapy. Leuk. Lymphoma., 43: 2281-2289, 2002.
9. Hughes, T. P., Kaeda, J., Branford, S., Rudzki, Z., Hochhaus, A., Hensley, M. L., Gathmann, I., Bolton, A. E., van Hoomissen, I. C., Goldman, J. M., and Radich, J. P. Frequency of major molecular responses to imatinib or interferon α plus cytarabine in newly diagnosed chronic myeloid leukemia. N. Engl. J. Med., 349: 1423-1432, 2003.
10. Pichert, G., Alyea, E. P., Soiffer, R. J., Roy, D. C., and Ritz, J. Persistence of myeloid progenitor cells expressing BCR-ABL mRNA after allogeneic bone marrow transplantation for chronic myelogenous leukemia. Blood, 84: 2109-2114, 1994.
11. Wu, C. J., Yang, X. F., McLaughlin, S., Neuberg, D., Canning, C., Stein, B., Alyea, E. P., Soiffer, R. J., Dranoff, G., and Ritz, J. Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia. J. Clin. Investig., 106: 705-714, 2000.